死后病理负荷与额颞叶变性临床进展速度的关联
本研究回顾性纳入101例额颞叶变性(FTLD-Tau或FTLD-TDP)患者,利用数字病理量化病理负荷,分析其与疾病 duration 及临床进展速度的关系。结果发现TDP-43负荷而非tau负荷与临床进展速度相关,提示不同蛋白病的聚集动态可能不同。
要点
- TDP-43病理负荷与CDR-SB和MMSE评估的临床进展速度相关。
- FTLD-Tau病理负荷与疾病 duration 或临床进展无关。
- 在bvFTD亚组中,TDP-43负荷而非病理分期与临床下降相关。
核心结论
- TDP-43病理负荷与生前临床下降更密切,而非疾病过程中的累积聚集。
- FTLD-Tau与FTLD-TDP的蛋白聚集时间动态可能不同。
研究设计与样本
- 回顾性队列研究,纳入101例FTLD-Tau或FTLD-TDP患者,均有纵向评估和神经病理诊断。
- 采用数字病理量化最多6个皮层区域的病理负荷,并构建FTLD-TDP病理分期。
- 使用线性回归和线性混合效应模型,调整半球、性别、发病年龄、致病变异状态和病理亚型。
主要发现
- 疾病 duration 与病理负荷无关(FTLD-TDP β=0.01 [-0.06, 0.09];p=0.7;FTLD-Tau β=0.1 [-0.4, 0.7];p=0.7)。
- 在FTLD-TDP患者中,平均TDP-43负荷与较差的CDR-SB(β=0.1 [0.06, 0.2];p=0.0001)和MMSE(β=-0.1 [-0.2, -0.03];p=0.009)相关。
- TDP-43分期也与较差的CDR-SB(β=0.07 [0.02, 0.1];p=0.005)和MMSE(β=-0.2 [-0.3, -0.1];p=0.000005)相关。
- 在局限于bvFTD的敏感性分析中,TDP-43负荷与CDR-SB(β=0.1 [0.03, 0.2];p=0.005)和MMSE(β=-0.2 [-0.4, -0.05];p=0.009)相对下降相关,而分期无显著关联。
临床怎么用
- TDP-43病理负荷可能作为FTLD-TDP临床进展的候选生物标志物。
- FTLD-Tau和FTLD-TDP特异性生物标志物的解读需考虑蛋白聚集动态差异。
局限性
- 回顾性研究设计。
- 样本量有限(101例)。
- 仅纳入两个中心数据库的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Histopathologic staging of Alzheimer disease has led to validation of imaging techniques that guide diagnosis and treatment. We previously constructed preliminary phases of the sequential progression of TDP-43 and tau to guide similar efforts in behavioral-variant frontotemporal dementia (bvFTD). In this article, we expand this work using digital pathology and longitudinal clinical data to more comprehensively model the relationship between clinical progression and the distribution and severity of postmortem frontotemporal lobar degeneration (FTLD) pathology. METHODS: In this retrospective cohort study, 101 patients (42% female, median age at symptom onset = 63 years) were selected from the Penn Integrated Neurodegenerative Disease Database and had both longitudinal assessments and primary neuropathologic diagnosis of FTLD-Tau or FTLD-TDP. We used validated methods to quantify the burden of primary pathology from up to 6 cortical regions across hemispheres. FTLD-TDP pathologic phase was constructed from diagnostic pathology data based on published criteria. We tested the association between pathologic metrics and (1) disease duration or (2) the rate of clinic progression measured by 2 independent global measures (Clinical Dementia Rating Scale-Sum of Boxes [CDR-SB] and Mini-Mental State Examination [MMSE]). Linear regression and linear mixed-effects models were adjusted for hemisphere sampled, sex, age at onset, pathogenic variant status, and pathologic subtype. RESULTS: Disease duration did not associate with pathologic burden in multiple regression (FTLD-TDP β = 0.01 [-0.06, 0.09]; p = 0.7; FTLD-Tau β = 0.1 [-0.4, 0.7]; p = 0.7). By contrast, mean TDP-43 burden, but not FTLD-Tau burden, was associated with both worse relative CDR-SB (β = 0.1 [0.06, 0.2]; p = 0.0001) and MMSE (β = -0.1 [-0.2, -0.03]; p = 0.009) among all FTLD-TDP patients. TDP-43 phase also associated with worse CDR-SB (β = 0.07 [0.02, 0.1]; p = 0.005) and MMSE (β = -0.2 [-0.3, -0.1]; p = 0.000005). TDP-43 burden (CDR-SB (β = 0.1 [0.03, 0.2]; p = 0.005 and MMSE (β = -0.2 [-0.4, -0.05]; p = 0.009)), but not phase (CDR-SB (β = 0.02 [-0.03, 0.08]; p = 0.4 and MMSE (β = -0.04 [-1, 0.07]; p = 0.5)), associated with relative decline in sensitivity analyses limited to bvFTD. DISCUSSION: Greater TDP-43 burden was most closely associated with antemortem clinical decline rather than cumulative aggregation through the disease course. These human data suggest that the temporal dynamics of protein aggregation may differ among FTLD proteinopathies, with implications for the interpretation of FTLD-Tau and FTLD-TDP‑specific biomarkers as these are developed.
引用
- Magee RG, Xie SX, Ohm DT, et al. Association Between Postmortem Pathologic Burden and the Rate of Clinical Progression in Patients With Frontotemporal Lobar Degeneration. Neurology. 2026. PMID: 42479989. doi:10.1212/WNL.0000000000218278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。